The approval of Biogen’s Alzheimer’s treatment could herald a new generation of therapies, but before that can happen, more investment and better diagnostics may be needed, explains Ben Har
Biogen has downbeat news about its gene therapy for the rare inherited eye disease, X-linked retinitis pigmentosa, announcing the shot failed to meet its target in a phase 2/3 study.
In this episode of our Health Innovators series, Paul Tunnah is joined by Teresa Arroyo-Gallego, chief data scientist at artificial intelligence technology company nQ Medical.
